Drugs / CT3001
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06598007 | Sep 2024 → Jun 2027 expected | colorectal cancer, pancreatic ductal adenocarcinoma | Crossignal Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT3001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06598007 ↗ |
| Action | Inhibit | “a small molecule inhibitor of GPR35” NCT06598007 ↗ |
| Modality | Small molecule | “a small molecule inhibitor of GPR35” NCT06598007 ↗ |
| Route | Oral | “administered CT3001 orally (QD or BID)” NCT06598007 ↗ |
| Target | GPR35 | “a small molecule inhibitor of GPR35” NCT06598007 ↗ |